Administrative Core

行政核心

• 批准号: 9151285
• 负责人: Michael S Gilmore
• 金额: $ 15.71万
• 依托单位: MASSACHUSETTS EYE AND EAR INFIRMARY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9151285
• 关键词: Anabolism; Antibiotic Resistance; Biochemistry; Biology; Cell Wall; Center for Translational Science Activities; Clinical Sciences; Clinical Treatment; Communication; Communities; Complement; Complex; Development; Ear; Enterococcus; Eye; Faculty; Fostering; General Hospitals; Genus staphylococcus; Goals; Individual; Infection; Knowledge; Massachusetts; Modeling; Molecular Biology; Multi-Drug Resistance; National Institute of Allergy and Infectious Disease; Participant; Pathogenesis; Prevention; Research Infrastructure; Resistance; Resources; Science; Scientist; Sum; System; Technology; Toxic effect; Universities; catalyst; data sharing; design; experience; implementation research; inhibitor/antagonist; medical schools; methicillin resistant Staphylococcus aureus; microbial; multi-drug resistant pathogen; multidisciplinary; next generation; novel; novel strategies; pathogen; prevent; programs; screening; success; tool

SUMMARY This Harvard-wide Program on Antibiotic Resistance (HPAR) proposal outlines the design and function of a novel, multidisciplinary, collaborative partnership to develop new approaches for treating and preventing multidrug resistant MRSA and VRE infection. Although discovery and delivery of novel and promising new compounds to the development pipeline is a major overall goal, because this is an academic effort, we also will add to the scientific knowledge that underpins the novel inhibitors developed; add to the understanding of resistance; and develop novel new tools for studying host-pathogen interactions and multidrug resistant pathogens. This project is being proposed by an accomplished group of scientists with extensive experience in the biochemistry of cell wall biosynthesis and use of that information to design screens and new inhibitors; the molecular biology of model host systems and the use of those systems in novel ways for screening compounds that hit complex targets with minimal toxicity; the development and application of high throughput next generation technologies; and the pathogenesis, biology and clinical treatment of infection caused by multidrug resistant staphylococci and enterococci. This scientific expertise is complemented by substantial administrative experience. The goal of the HPAR Administrative Core therefore is to oversee the smooth implementation of the research plan and deployment of resources, and to foster the cohesive and well functioning whole to achieve goals that are greater than the sum of the individual projects. This will be accomplished by achieving the following Specific Aims: 1) Provide program management, oversight, and compliance assurance, 2) Facilitate interactions between participants from the various components of the Harvard Medical School (including faculty located on the Longwood Campus, at Massachusetts General Hospital, and the Massachusetts Eye and Ear Infirmary), and the Mylonakis lab now in part at Brown University – in a smooth and effective manner; 3) Provide critical infrastructure for fiscal management of the program; 4) Provide connectivity to and leverage other Harvard-wide initiatives, including the Microbial Sciences Initiative (MSI), and Catalyst Clinical and Translational Sciences Center; and 5) Provide a single point of contact and active coordination for on-going communication with NIAID, the Program Officer, and other NIAID staff and initiatives. The Administrative Core has managed the previous period in a way that led to a highly functioning, well integrated, and synergistic whole, and achieved additional aims generating resources and fostering data sharing with the greater scientific community. The proposed continuation period will build on these successes.

概括 哈佛大学范围内的抗生素耐药性计划 (HPAR) 提案概述了一个抗生素耐药性的设计和功能 新颖的多学科合作伙伴关系，开发新的治疗和预防方法 尽管发现并提供了新型且有前途的新感染，但具有多重耐药性 MRSA 和 VRE 感染。 化合物的开发管线是一个主要的总体目标，因为这是一项学术工作，我们也将 增加支持所开发的新型抑制剂的科学知识；增加对以下物质的理解； 耐药性；并开发用于研究宿主-病原体相互作用和多药耐药性的新型工具 该项目是由一群在病原体方面拥有丰富经验的杰出科学家提出的。 细胞壁生物合成的生物化学以及利用该信息设计筛选和新抑制剂； 模型宿主系统的分子生物学以及以新方式使用这些系统来筛选化合物 以最小的毒性击中复杂的目标；接下来是高通量的开发和应用； 产生技术；以及多种药物引起的感染的发病机制、生物学和临床治疗 耐药葡萄球菌和肠球菌的科学专业知识得到大量行政管理的补充。 因此，HPAR 管理核心的目标是监督项目的顺利实施。 研究计划和资源部署，并促进有凝聚力和运作良好的整体 实现大于各个项目总和的目标 这将通过实现来实现。 以下具体目标：1) 提供项目管理、监督和合规保证，2) 促进哈佛医学院各个部门的参与者之间的互动 （包括位于马萨诸塞州总医院朗伍德校区的教职人员，以及 马萨诸塞州眼耳医院），以及现在部分位于布朗大学的迈洛纳基斯实验室 - 进展顺利 和有效的方式； 3) 为该计划的财务管理提供关键的基础设施； 连接并利用哈佛范围内的其他计划，包括微生物科学计划（MSI）， Catalyst 临床和转化科学中心；以及 5) 提供单点联系和主动联系 协调与 NIAID、项目官员以及其他 NIAID 工作人员和倡议的持续沟通。 行政核心在前一时期的管理方式导致了一个高度运作、良好的 整合、协同的整体，并实现了生成资源和培育数据的额外目标 与更广泛的科学界分享的建议的延续期将建立在这些成功的基础上。